Investment Thesis
AIM ImmunoTech is in critical financial distress with negative stockholders' equity of -$6.1M, indicating liabilities exceed assets by a substantial margin. The company generated only $67K in revenue against $9.8M in net losses, with operating cash flow of -$9.0M, demonstrating severe operational dysfunction and inability to generate sustainable revenue. With 9 months of cash burn at current rates remaining before depletion, the company faces imminent solvency risk unless it secures immediate capital or achieves dramatic operational turnaround.
AIM Strengths
- Maintains $2.3M in cash reserves providing near-term liquidity cushion
- Recent insider activity (5 Form 4 filings in 90 days) suggests management engagement
- Operates in biologics sector with potential for breakthrough therapies if pipeline succeeds
AIM Risks
- Negative stockholders' equity of -$6.1M indicates technical insolvency and shareholder dilution risk
- Revenue of $67K against $9.8M net loss indicates fundamentally broken business model
- Operating cash burn of $9.0M annually will deplete cash reserves in approximately 3 months at current burn rate
- Current ratio of 0.64x indicates inability to meet short-term obligations
- Extreme negative margins (-13,003% operating margin) demonstrate complete lack of operational profitability
Key Metrics to Watch
- Cash balance and runway until capital raise or insolvency
- Monthly revenue growth trajectory and pipeline advancement
- Operating cash burn rate and path to cash flow breakeven
- Stockholders' equity recovery through capital injection or operational profitability
AIM Financial Metrics
AIM Profitability Ratios
AIM Balance Sheet & Liquidity
AIM 5-Year Financial Trend
5-Year Trend Summary: AIM ImmunoTech Inc.'s revenue has grown significantly by 24% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.60 indicates the company is currently unprofitable.
AIM Growth Metrics (YoY)
AIM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $26.0K | -$1.8M | $1.57 |
| Q2 2025 | $25.0K | -$1.8M | $-3.00 |
| Q1 2025 | $16.0K | -$3.7M | $-0.05 |
| Q3 2024 | $35.0K | -$3.7M | $-0.06 |
| Q2 2024 | $42.0K | -$1.8M | $-0.03 |
| Q1 2024 | $40.0K | -$3.7M | $-0.08 |
| Q3 2023 | $21.0K | -$6.4M | $-0.13 |
| Q2 2023 | $30.0K | -$4.9M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AIM Capital Allocation
AIM SEC Filings
Access official SEC EDGAR filings for AIM ImmunoTech Inc. (CIK: 0000946644)